Dr. Reddy’s has expanded its commercial operations in Europe with the introduction of its range of generic drugs in France.
Dr. Reddy’s Laboratories has expanded its commercial operations in Europe with the introduction of its range of generic drugs in France. The first products, which include cancer drugs, anti-infectives, and antimycotics, will be made available in the hospital market in March 2017.
The company also recently launched select products of its hospital portfolio in Italy and Spain, and is looking to expand its business in these regions with the launch of anti-HIV products this year.
Dr. Reddy’s has a portfolio of injectables and complex generic drugs. The company currently has two R&D centres, one manufacturing, and a packaging and storage facility in Europe.
Source: Dr. Reddy’s
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.